Literature DB >> 1317639

Analysis of uterine contractility after administration of the non-steroidal anti-inflammatory drug nimesulide.

M Pulkkinen1, T Monti, A Macciocchi.   

Abstract

To study the effects of non-steroidal anti-inflammatory drugs (NSAIDs) on uterine contractility in different parts of the uterus and on the direction and velocity of propagation of the activity, intra-uterine pressure (IUP) was measured simultaneously in 10 dysmenorrheic and 5 eumenorrheic patients with two microtransducer catheters at two locations (30 mm apart) before and after taking nimesulide, a newly developed NSAID. The uterus developed higher pressure cycles in the fundus than in the isthmus, in both eumenorrheic and dysmenorrheic conditions. Nimesulide did not affect either the active pressure (AP) or the direction and velocity of propagation of the activity, though it alleviated pain significantly. In dysmenorrheic patients, resting pressure (RP) is at a high level only in the fundus. The velocity of propagation ranged from 12 to 19 mm/s. The mathematical probability of procervical activity (1.0 if all procervical; 0.0 if all profundal), and thus the transport, was 0.59 in eumenorrheic and 0.68 in dysmenorrheic patients, the average for the whole series being 0.65. The luminal content (menstrual blood) moves in the cervical direction much more slowly than would be expected on the basis of simple calculations of velocity (velocity vector) of propagation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1317639     DOI: 10.3109/00016349209009915

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  2 in total

1.  Crossover study of glyceryl trinitrate patches for controlling pain in women with severe dysmenorrhoea.

Authors:  R Pittrof; C Lees; C Thompson; A Pickles; J F Martin; S Campbell
Journal:  BMJ       Date:  1996-04-06

Review 2.  Nimesulide in dysmenorrhoea.

Authors:  M Pulkkinen
Journal:  Drugs       Date:  1993       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.